Insider Selling: Pyxis Oncology (NASDAQ:PYXS) Director Sells $14,312.88 in Stock

Pyxis Oncology, Inc. (NASDAQ:PYXS) Director Rachel Humphrey sold 13,896 shares of the company’s stock in a transaction on Monday, April 21st. The stock was sold at an average price of $1.03, for a total transaction of $14,312.88. Following the transaction, the director directly owned 81,309 shares in the company, valued at approximately $83,748.27. This trade represents a 14.60% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Pyxis Oncology Stock Down 5.8%

Shares of NASDAQ PYXS opened at $1.31 on Friday. Pyxis Oncology, Inc. has a 52 week low of $0.83 and a 52 week high of $5.55. The firm has a 50-day moving average price of $1.49 and a 200 day moving average price of $2.49. The stock has a market capitalization of $82.31 million, a price-to-earnings ratio of -1.02 and a beta of 1.45.

Pyxis Oncology (NASDAQ:PYXS) last issued its earnings results on Monday, March 23rd. The company reported ($0.29) earnings per share for the quarter, topping the consensus estimate of ($0.35) by $0.06. The company had revenue of $11.04 million for the quarter, compared to analyst estimates of $0.13 million. Equities research analysts expect that Pyxis Oncology, Inc. will post -1.04 EPS for the current fiscal year.

Analysts Set New Price Targets

PYXS has been the subject of several research analyst reports. Wall Street Zen raised Pyxis Oncology from a “sell” rating to a “hold” rating in a research note on Saturday. HC Wainwright reiterated a “buy” rating and set a $7.00 target price on shares of Pyxis Oncology in a research report on Tuesday. Royal Bank Of Canada lowered their target price on Pyxis Oncology from $8.00 to $5.00 and set an “outperform” rating on the stock in a report on Thursday, December 18th. Stifel Nicolaus dropped their price target on Pyxis Oncology from $9.00 to $8.00 and set a “buy” rating for the company in a research report on Tuesday. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Pyxis Oncology in a research note on Thursday, January 22nd. Five analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $7.00.

Key Stories Impacting Pyxis Oncology

Here are the key news stories impacting Pyxis Oncology this week:

• Positive Sentiment: HC Wainwright reiterated a “Buy” and materially lifted multiple forward EPS forecasts (FY2026, FY2027, FY2028 and projected FY2030 profitability) and bumped several quarterly estimates — signaling improved multi‑year expectations and a $7 price target. These revisions are a bullish catalyst for upside longer term. HC Wainwright Lifts Earnings Estimates for Pyxis Oncology HC Wainwright Reaffirms Buy for Pyxis Oncology
• Neutral Sentiment: Market data shows an apparent zero reported short interest for March (likely a reporting artifact); this provides no reliable directional signal for near‑term price pressure.
• Negative Sentiment: Insider selling: Director Rachel Humphrey disclosed sales (most recently 13,896 shares at about $1.03). Insider exits can be viewed negatively by investors even if done for personal/liquidity reasons. Insider Selling Disclosure
• Negative Sentiment: Some sell‑side shops trimmed upside: Stifel lowered its price target (reducing implied upside), a sign that not all analysts are uniformly bullish. That can temper buying interest. Stifel Lowers Expectations for Pyxis Oncology
• Negative Sentiment: Within HC Wainwright’s note there was a downward revision to Q2‑2026 EPS (to -$0.36 from -$0.32), introducing mixed near‑term guidance despite the more positive multi‑year outlook — likely contributing to short‑term selling pressure.

Institutional Investors Weigh In On Pyxis Oncology

Several hedge funds have recently modified their holdings of PYXS. Laurion Capital Management LP grew its stake in Pyxis Oncology by 32.3% in the 4th quarter. Laurion Capital Management LP now owns 4,796,479 shares of the company’s stock worth $5,516,000 after acquiring an additional 1,170,505 shares during the period. Atle Fund Management AB purchased a new position in shares of Pyxis Oncology during the 4th quarter worth $710,000. Bank of America Corp DE lifted its stake in shares of Pyxis Oncology by 2,690.9% during the 3rd quarter. Bank of America Corp DE now owns 615,922 shares of the company’s stock worth $1,367,000 after purchasing an additional 593,853 shares during the period. Longaeva Partners L.P. acquired a new stake in shares of Pyxis Oncology during the third quarter worth $1,117,000. Finally, Jane Street Group LLC boosted its holdings in shares of Pyxis Oncology by 158.8% during the fourth quarter. Jane Street Group LLC now owns 786,010 shares of the company’s stock worth $904,000 after purchasing an additional 482,310 shares during the last quarter. 39.09% of the stock is owned by institutional investors and hedge funds.

Pyxis Oncology Company Profile

Pyxis Oncology (NASDAQ: PYXS) is a clinical‐stage biotechnology company focused on the discovery and development of targeted oncology therapies. The company’s platform centers on antibody‐drug conjugates (ADCs) that deliver potent mitotic inhibitors directly to cancer cells, leveraging novel payloads designed to disrupt cell division. By combining highly specific antibodies with innovative cytotoxic agents, Pyxis Oncology aims to improve therapeutic windows and reduce off‐target toxicities common to conventional chemotherapies.

Since its inception, Pyxis Oncology has built a pipeline of early‐stage ADC candidates directed against a variety of solid tumor antigens.